|
----- Original Message -----
From: Rob
Sent: Friday, July 08, 2005 1:18 PM
Subject: [AMN107] AMN107, a Novel Aminopyrimidine Inhibitor of
Bcr-Abl,Has In vitro Activity against Imatinib-Resistant ChronicMyeloid
Leukemia. Resistance to or intolerance of imatinib in patients with Philadelphia
chromosome-positive chronic myelogenous leukemia (CML) has encouraged the
development of more potent Bcr-Abl inhibitors. AMN107 is a novel, orally
bioavailable ATP-competitive inhibitor of Bcr-Abl. The effects of AMN107 were
compared with those of imatinib on imatinib-sensitive (KBM5 and KBM7) and
imatinib-resistant CML cell lines (KBM5-STI571(R1.0) and KBM7-STI571(R1.0)).
[AMN107] A groups for the AMN107 clinical trial A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML YAHOO! GROUPS LINKS
|
